Stocks
Vaxcyte, Inc.PCVX
NASDAQHealthcareBiotechnology$54.58-2.90%
A clinical-stage biotechnology company focused on developing novel vaccines to prevent or treat bacterial infections, leveraging its proprietary XpressCF platform. Investors monitor its progress due to its potential to address antibiotic resistance and its pipeline targeting pneumococcal disease. The company’s market valuation reflects optimism around its lead candidate, VAX-24.
Market Cap: $7.9B52W Range: $27.66 – $76.61
Congressional Interest in Vaxcyte, Inc. (PCVX)
3 members of Congress have disclosed 6 trades in Vaxcyte, Inc. (PCVX), a Healthcare company. The buy/sell breakdown shows 4 purchases versus 2 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
6
Unique Politicians
3
Buys
4
Sells
2
Who in Congress Is Trading PCVX?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-04-28 | Gilbert Cisneros | buy | $1K – $15K |
| 2025-04-15 | Gilbert Cisneros | buy | $1K – $15K |